| Ytd | 6.54% | |
| 1y | 40.53% |
| Open | 38.95 | Prev Close | 39.01 | Low | 36.96 | High | 39.66 | Mkt Cap | 4.35B |
| Vol | 3.10M | Avg Vol | 2.39M | EPS | -4.15 | P/E | N/A | Forward P/E | -8.54 |
| Beta | 0.68 | Short Ratio | 11.81 | Inst. Own | 64.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 31.79 | 200-d Avg | 32.86 | 1yr Est | 92.58 |
VKTX News
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting
Viking Therapeutics' pipeline includes several promising weight-loss candidates. The stock could soa
Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key dif
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or H
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near t
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss ma
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pip
Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin recepto
Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical compa
A global semiconductor sell-off hammered the Nasdaq on Tuesday, but a rotation into defensives and s
